These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 1736531)

  • 21. Poxvirus-based Japanese encephalitis vaccine candidates induce JE virus-specific CD8+ cytotoxic T lymphocytes in mice.
    Konishi E; Kurane I; Mason PW; Shope RE; Ennis FA
    Virology; 1997 Jan; 227(2):353-60. PubMed ID: 9018134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity of a purified fragment of 17D yellow fever envelope protein.
    Brandriss MW; Schlesinger JJ; Walsh EE
    J Infect Dis; 1990 Jun; 161(6):1134-9. PubMed ID: 1693159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses.
    Brandriss MW; Schlesinger JJ; Walsh EE; Briselli M
    J Gen Virol; 1986 Feb; 67 ( Pt 2)():229-34. PubMed ID: 3944585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of protective immunity elicited by recombinant vaccinia viruses that synthesize E or NS1 of Japanese encephalitis virus.
    Konishi E; Pincus S; Fonseca BA; Shope RE; Paoletti E; Mason PW
    Virology; 1991 Nov; 185(1):401-10. PubMed ID: 1833876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Baculovirus surface display of a chimeric E-NS1 protein of YFV protects against YFV infection.
    Tomatis C; Ferrer MF; Aquila S; Thomas PD; Arrías PN; Ferrelli L; Pidre M; Romanowski V; Carrera Silva EA; Gómez RM
    Vaccine; 2024 Nov; 42(25):126045. PubMed ID: 38852036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
    Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
    J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccinia virus-expressed bovine ephemeral fever virus G but not G(NS) glycoprotein induces neutralizing antibodies and protects against experimental infection.
    Hertig C; Pye AD; Hyatt AD; Davis SS; McWilliam SM; Heine HG; Walker PJ; Boyle DB
    J Gen Virol; 1996 Apr; 77 ( Pt 4)():631-40. PubMed ID: 8627251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection
    Douam F; Soto Albrecht YE; Hrebikova G; Sadimin E; Davidson C; Kotenko SV; Ploss A
    mBio; 2017 Aug; 8(4):. PubMed ID: 28811340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protective immune responses to the E and NS1 proteins of Murray Valley encephalitis virus in hybrids of flavivirus-resistant mice.
    Hall RA; Brand TN; Lobigs M; Sangster MY; Howard MJ; Mackenzie JS
    J Gen Virol; 1996 Jun; 77 ( Pt 6)():1287-94. PubMed ID: 8683218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduction of yellow fever virus mouse neurovirulence by immunization with a bacterially synthesized non-structural protein (NS1) fragment.
    Cane PA; Gould EA
    J Gen Virol; 1988 Jun; 69 ( Pt 6)():1241-6. PubMed ID: 3133449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunological and virological characterization of improved construction of recombinant vaccinia virus expressing rinderpest virus hemagglutinin.
    Asano K; Tsukiyama K; Shibata S; Yamaguchi K; Momoki T; Maruyama T; Kohara M; Miki K; Sugimoto M; Yoshikawa Y
    Arch Virol; 1991; 116(1-4):81-90. PubMed ID: 2001178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mice immunized with recombinant vaccinia virus expressing dengue 4 virus structural proteins with or without nonstructural protein NS1 are protected against fatal dengue virus encephalitis.
    Bray M; Zhao BT; Markoff L; Eckels KH; Chanock RM; Lai CJ
    J Virol; 1989 Jun; 63(6):2853-6. PubMed ID: 2724416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice.
    Bassi MR; Larsen MA; Kongsgaard M; Rasmussen M; Buus S; Stryhn A; Thomsen AR; Christensen JP
    PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004464. PubMed ID: 26886513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses.
    Guy B; Guirakhoo F; Barban V; Higgs S; Monath TP; Lang J
    Vaccine; 2010 Jan; 28(3):632-49. PubMed ID: 19808029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins.
    Taylor J; Weinberg R; Tartaglia J; Richardson C; Alkhatib G; Briedis D; Appel M; Norton E; Paoletti E
    Virology; 1992 Mar; 187(1):321-8. PubMed ID: 1736535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The early cellular signatures of protective immunity induced by live viral vaccination.
    Kohler S; Bethke N; Böthe M; Sommerick S; Frentsch M; Romagnani C; Niedrig M; Thiel A
    Eur J Immunol; 2012 Sep; 42(9):2363-73. PubMed ID: 22733156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparing immunogenicity and protective efficacy of the yellow fever 17D vaccine in mice.
    Ma J; Boudewijns R; Sanchez-Felipe L; Mishra N; Vercruysse T; Buh Kum D; Thibaut HJ; Neyts J; Dallmeier K
    Emerg Microbes Infect; 2021 Dec; 10(1):2279-2290. PubMed ID: 34792431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term sterilizing immunity to rinderpest in cattle vaccinated with a recombinant vaccinia virus expressing high levels of the fusion and hemagglutinin glycoproteins.
    Verardi PH; Aziz FH; Ahmad S; Jones LA; Beyene B; Ngotho RN; Wamwayi HM; Yesus MG; Egziabher BG; Yilma TD
    J Virol; 2002 Jan; 76(2):484-91. PubMed ID: 11752138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response.
    van Der Most RG; Murali-Krishna K; Ahmed R; Strauss JH
    J Virol; 2000 Sep; 74(17):8094-101. PubMed ID: 10933719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1.
    Schlesinger JJ; Brandriss MW; Cropp CB; Monath TP
    J Virol; 1986 Dec; 60(3):1153-5. PubMed ID: 3783816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.